🌟 Season’s Greetings from Occlutech! ❄️ As we close out the year, we reflect on our mission to improve the quality of life for people with heart conditions. This journey would not be possible without the dedication of our team and the support of our partners and healthcare professionals. Thank you for being part of our story. Wishing you a joyful holiday season and a healthy, prosperous New Year! 💙 #SeasonsGreetings #HappyHolidays #Everybeatcounts #TeamOcclutech
Occlutech
Tillverkning av medicintekniska produkter
Helsingborg, Helsingborg 13 793 följare
Every beat counts.
Om oss
Occlutech is a leading specialist provider of minimally invasive cardiac devices, with a mission to improve the quality of life for people with heart conditions. Since 2003, Occlutech has developed, produced, and commercialized first-class, minimally invasive, cardiac implants for Congenital Heart Disease, Stroke Prevention, and Heart Failure, all with the mission to improve patients’ lives and address unmet medical needs. The devices are sold to hospitals and clinics in over 80 countries and used by physicians in implantation procedures. Registered in Switzerland, Occlutech employs around 330 people and has manufacturing and R&D facilities in Germany and Türkiye, a global finance and distribution hub located in Helsingborg, Sweden, as well as clinical operations in Minneapolis, U.S.
- Webbplats
-
http://www.occlutech.com
Extern länk för Occlutech
- Bransch
- Tillverkning av medicintekniska produkter
- Företagsstorlek
- 201–500 anställda
- Huvudkontor
- Helsingborg, Helsingborg
- Typ
- Privatägt företag
- Grundat
- 2003
- Specialistområden
- Structural heart disease, Heart failure, Congenital Heart Disease, Stroke Prevention, Adult Intervention, ASD closure, PFO closure, Paravalvular Leak closure, PDA closure, VSD closure och LAA
Adresser
-
Primär
Landskronavägen 2
Helsingborg, Helsingborg 25232, SE
-
Wildenbruchstraße 15
Jena, Thuringia 07745, DE
-
Yeşilköy SB Mah. E Blok Sok
Occlutech Apt. No:6
Istanbul, Bakırköy/Istanbul 34149, TR
-
9325 Upland Lane North
Suite 3015
Maple Grove, Minnesota 55369, US
Anställda på Occlutech
Uppdateringar
-
Collaborating with partners like B. Braun Interventional Systems Inc. is what makes our mission possible. Our CCO’s recent visit to Pennsylvania was a great opportunity to reflect on what we’ve achieved in 2024 and align on priorities for 2025. Strong partnerships like this are key to advancing care for patients with heart conditions and driving meaningful innovation. #Occlutech #Everybeatcounts #Collaboration
Had a fantastic visit with our U.S. partner, B. Braun Interventional Team, in Pennsylvania this week! It was a great opportunity to connect in person, reflect on our achievements in 2024, and align on strategies for 2025. Excited for the growth ahead and the continued impact we will make together! #Occlutech #BBraun #Only1Team #partnership
-
🔮 Looking Ahead to the Future 🔮 Reaching over 100,000 sales of the Occlutech ASD Occluder is just the beginning. We continue to innovate and partner with healthcare professionals to push the boundaries of what’s possible in cardiac care. Together, we can achieve even greater milestones. ISI: https://lnkd.in/exWHR2Vp #Atrialseptaldefect #ASD #Occlutech #Everybeatcounts
-
We're #hiring a new Senior RA Specialist in Istanbul. Apply today or share this post with your network.
-
We're #hiring a new Supply Chain Assistant in Jena, Thuringia. Apply today or share this post with your network.
-
We're #hiring a new Group Business Controller in Helsingborg, Skåne County. Apply today or share this post with your network.
-
🌍 Making a Global Impact 🌍 With over 100,000 Occlutech ASD Occluders sold worldwide, our impact on cardiac care spans across continents. From Europe to Asia, the Americas to Africa, we are proud to support healthcare professionals in delivering quality care to their patients. Here’s to global health and the continuous pursuit of excellence. ISI: https://lnkd.in/exWHR2Vp #Atrialseptaldefect #ASD #Occlutech #Everybeatcounts
-
🚨 #AEPC2025 Alert – Final week to submit your abstract. Don't miss the deadline—submit your work by Monday, 16 December.
⏰ #AEPC2025 alert - Final week of abstract submission! Make sure to submit your abstract by Monday 16 December ► Submit your abstract here: https://bit.ly/4dMIAkk
-
🚀 Advancing Cardiac Care Together 🚀 The success of the Occlutech ASD Occluder, with over 100,000 units sold globally[1], underscores our commitment to innovation and excellence in cardiac care. We remain dedicated to developing solutions that improve patient quality of life. Join us in celebrating this milestone and looking forward to future advancements. Scroll through the carousel to learn more 👉 ISI: https://us.occlutech.com/ [1] data on file
-
Ease of Use for Better Outcomes ⏱️ In the only randomized controlled clinical trial comparing two ASD closure devices, the Occlutech ASD Occluder achieved a higher rate of successful defect closure with less major complications[1]. 1: Kenny D et al., Catheter Cardiovasc Interv. 2019 Feb 1;93(2):316-321. ISI: https://us.occlutech.com/ 👉 Swipe through the carousel to see the key findings: